Search
for
Sort by
Research 61–90 of 1000+
- Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
- Topical 2% tofacitinib for children with alopecia areata, alopecia totalis, and alopecia universalis
- Experience with oral tofacitinib in 8 adolescent patients with alopecia universalis
- Alefacept for Severe Alopecia Areata
- A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata
- Objective outcome measures: Collecting meaningful data on alopecia areata
- Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers
- Tofacitinib for the Treatment of Severe Alopecia Areata in Adults and Adolescents
- Effectiveness and safety of baricitinib in patients with severe alopecia areata: a 36-week multicenter real-world experience
- Dupilumab therapy for alopecia areata in pediatric patients with concomitant atopic dermatitis
- Clinical experiences on alopecia areata treatment with tofacitinib: A study of 63 patients
- Treatment of moderate-to-severe alopecia areata in pre-adolescent children with baricitinib
- Platelet-Rich Plasma in Alopecia Areata—A Steroid-Free Treatment Modality: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
- Rethinking the classification of alopecia areata
- Successful treatment of resistant alopecia areata with a phototoxic dose of ultraviolet A after topical 8‐methoxypsoralen application
- Janus Kinase Inhibitors for Alopecia Areata
- Mild-to-moderate COVID-19 is not associated with worsening of alopecia areata: A retrospective analysis of 32 patients
- Response of alopecia areata of the beard to oral tofacitinib
- Rebound effect associated with JAK inhibitor use in the treatment of alopecia areata
- Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis
- Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Wharton’s jelly-derived mesenchymal stem cells in the treatment of four patients with alopecia areata
- Dietary Habits in Japanese Patients with Alopecia Areata
- European expert consensus statement on the systemic treatment of alopecia areata
- 67 Patterns of clinical response in patients with alopecia areata (AA) treated with ritlecitinib in the ALLEGRO phase 2b/3 and ongoing, phase 3, ALLEGRO-LT studies
- LB785 Efficacy and safety of baricitinib in adults with Alopecia Areata: Phase 3 results from a randomized controlled trial (BRAVE-AA1)
- Serum interleukin-37 and its gene polymorphism (rs3811047) in Egyptian patients with alopecia areata